LIGA 20

a semisynthetic GM1 ganglioside with N-dichloroacetylsphingosine; about ten times more potent than the natural GM2 in protecting neurons in culture against glutamate toxicity

Also Known As:

II3Neu5-AcGgOse4-2-d-erythro-1,3-dihydroxy-2-dichloroacetamide-4-trans-octadacene; LIGA-20; LIGA20; Acetamide, N-(1-(((O-(N-acetyl-alpha-neuraminosyl)-(2-3)-O-(O-beta-D-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4))-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl)oxy)methyl)-2-hydroxy-3-heptadecenyl)-2,2-dichloro-, (R-(R*,S*-(E)))-

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Wu, Gusheng: 5 articles (09/2011 - 11/2005)
2.	Ledeen, Robert W: 4 articles (09/2011 - 11/2005)
3.	Lu, Zi-Hua: 2 articles (09/2011 - 11/2005)
4.	Amin, Ruchi: 1 article (09/2011)
5.	Kulkarni, Neil: 1 article (09/2011)
6.	Ledeen, Robert: 1 article (11/2007)
7.	Meyenhofer, Markus F: 1 article (11/2005)
8.	Wang, Jianfeng: 1 article (11/2005)
9.	Wang, Yvette: 1 article (11/2005)
10.	Xie, Xin: 1 article (11/2005)

Related Diseases

1.	Seizures (Absence Seizure) 04/01/2006 - "As further indication of Ca2+ dysregulation, the mutant mice were highly susceptible to kainite-induced seizures which were attenuated by LIGA-20. " 03/01/2006 - "The seizures were effectively attenuated by LIGA20 in parallel with the ability of this agent to enter brain cells, insert into the NE, and potentiate Na(+)/Ca(2+) exchange activity in the nucleus. " 11/01/2007 - "Further indication came from a study of the mutant mice, which were highly susceptible to kainate-induced seizures and could be rescued by LIGA-20. " 11/23/2005 - "Enhanced susceptibility to kainate-induced seizures, neuronal apoptosis, and death in mice lacking gangliotetraose gangliosides: protection with LIGA 20, a membrane-permeant analog of GM1."
2.	Infarction (Infarctions) 07/05/1994 - "The N-dichloroacetylsphingosine derivative of lysoGM1 (LIGA20) administered after the lesion either i.v. or per or reduces the infarct size by 30-40% and attenuates the associated cognition deficits, presumably by limiting the extent of damage of neurons at risk located in the surroundings of the infarcted core (i.e., area penumbra). " 01/01/1994 - "Oral treatment with 100 mg/kg of LIGA20 reduced the infarct size in the cortex but not in the ischemic core (the striatum). " 07/05/1994 - "LIGA20, a lyso derivative of ganglioside GM1, given orally after cortical thrombosis reduces infarct size and associated cognition deficit." 01/01/1994 - "Orally administered glycolipid derivative LIGA20 reduces infarct volume and behavioral impairment after focal cerebral ischemia."
3.	Cognitive Dysfunction 01/01/1994 - "Oral administration of 50 to 200 mg/kg of LIGA20, initiated 24 hr before middle cerebral artery occlusion and continued for 7 days, reduced the motor and cognitive impairment after the stroke, measured by the rotarod and the passive avoidance test, respectively. "
4.	Parkinsonian Disorders (Parkinsonism) 09/01/2011 - "These manifestations of parkinsonism were largely attenuated by administration of LIGA-20, a membrane permeable analog of GM1 that penetrates the blood brain barrier and enters living neurons. "
5.	Stroke (Strokes) 01/01/1994 - "semisynthetic glycolipid LIGA20 (II3Neu5-AcGgOse4-2-d-erythro-1,3-dihydroxy-2-dichloro-aceta mide-4-trans- octadecene) treatment in stroke was studied in a permanent left middle cerebral artery occlusion model in the rat. " 01/01/1994 - "Oral administration of 50 to 200 mg/kg of LIGA20, initiated 24 hr before middle cerebral artery occlusion and continued for 7 days, reduced the motor and cognitive impairment after the stroke, measured by the rotarod and the passive avoidance test, respectively. "

Related Drugs and Biologics

1.	Kainic Acid (Kainate)
2.	Glycolipids
3.	Gangliosides
4.	G(M1) Ganglioside
5.	gangliotetraose

Related Therapies and Procedures

1.	Oral Administration